← Search & browse all drugs
CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › ANTIARRHYTHMICS, CLASS I AND III › Antiarrhythmics, class Ia
ajmaline
C01BA05
Forms & Strengths
- Tablets: 10mg, 20mg, 30mg, 50mg, 100mg
- Injectable solution: 10mg/mL, 20mg/mL, 50mg/mL
Adult Dosing
- Oral: 10-50mg every 6-12 hours as needed
- IV: 20-50mg over 2-5 minutes, may repeat after 10-30 minutes
Pediatric Dosing
- Not recommended for children under 12 years old due to limited data
- For children over 12 years old, follow adult dosing with caution
Indications
- Ventricular arrhythmias, especially during myocardial infarction
- Supraventricular tachycardia, atrial fibrillation, atrial flutter
- Prevention of paroxysmal atrial tachycardia
Mechanism of Action
- Class Ia antiarrhythmic, blocks sodium and potassium channels
- Increases effective refractory period and reduces automaticity
- Reduces conduction velocity and prolongs repolarization
Contraindications
- Severe sinus node dysfunction, AV block, or bundle branch block
- Chronic obstructive pulmonary disease (COPD) or asthma
- Myasthenia gravis or other neuromuscular disorders
Adverse Reactions
- Nausea, vomiting, diarrhea, anorexia, fatigue
- CNS effects: headache, dizziness, confusion, hallucinations
- Cardiovascular effects: hypotension, cardiac arrest, arrhythmias
Drug Interactions
- Beta blockers: increased risk of cardiac depression and arrhythmias
- Calcium channel blockers: increased risk of hypotension and AV block
- Phenobarbital, rifampicin: decreased ajmaline levels
Curated Content: Needs Vetting Before Put to Clinical Use